RNA-Targeting CRISPR

Scientists identify a novel CRISPR system that zeroes in on single-stranded RNA.

Written byAnna Azvolinsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, NIH IMAGE GALLERYMuch attention paid to the bacterial CRISPR/Cas9 system has focused on its uses as a gene-editing tool. But there are other CRISPR/Cas sytems. Researchers from MIT and the National Center for Biotechnology Information (NCBI) last year identified additional CRISPR proteins. One of these proteins, C2c2, seemed to be a putative RNA-cleaving—rather than a DNA-targeting—enzyme, the researchers reported at the time. Now, the same group has established that C2c2 indeed cleaves single-stranded RNA (ssRNA), providing the first example of a CRISPR/Cas system that exclusively targets RNA. The team’s latest results, published today (June 2) in Science, confirm the diversity of CRISPR systems and point to the possibility of precise in vivo RNA editing.

“This protein does what we expected, performing RNA-guided cleavage of cognate RNA with high specificity, and can be programmed to cleave any RNA at will,” study coauthor Eugene Koonin, of the NCBI and the National Library of Medicine, told The Scientist.

“I am very excited about the paper,” said Gene Yeo, an RNA researcher at the University of California, San Diego, who was not involved in the work. “The community was expecting to find native RNA CRISPR systems, so it’s great that one of these has now been characterized.”

The researchers originally identified C2c2 in Leptotrichia shahii in a systematic search for previously unidentified CRISPR systems within diverse bacterial genomes. For the present study, the team focused on C2c2, as its sequence contained two copies ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery